Nasal Colivelin treatment ameliorates memory impairment related to Alzheimer's disease

Marina Yamada, Tomohiro Chiba, Jumpei Sasabe, Kenzo Terashita, Sadakazu Aiso, Masaaki Matsuoka

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Humanin (HN) and its derivatives, such as Colivelin (CLN), suppress neuronal death induced by insults related to Alzheimer's disease (AD) by activating STAT3 in vitro. They also ameliorate functional memory impairment of mice induced by anticholinergic drugs or soluble toxic amyloid-β (Aβ) in vivo when either is directly administered into the cerebral ventricle or intraperitoneally injected. However, the mechanism underlying the in vivo effect remains uncharacterized. In addition, from the standpoint of clinical application, drug delivery methods that are less invasive and specific to the central nervous system (CNS) should be developed. In this study, we show that intranasally (i.n.) administered CLN can be successfully transferred to CNS via the olfactory bulb. Using several behavioral tests, we have demonstrated that i.n. administered CLN ameliorates memory impairment of AD models in a dose-responsive manner. Attenuation of AD-related memory impairment by HN derivatives such as CLN appears to be correlated with an increase in STAT3 phosphorylation levels in the septohippocampal region, suggesting that anti-AD activities of HN derivatives may be mediated by activation of STAT3 in vivo as they are in vitro. We further demonstrate that CLN treatment inhibits an Aβ induced decrease in the number of choline acetyltransferase (ChAT)-positive neurons in the medial septum. Combined with the finding that HN derivatives upregulate mRNA expression of neuronal ChAT and vesicular acetylcholine transporter (VAChT) in vitro, it is assumed that CLN may ameliorate memory impairment of AD models by supporting cholinergic neurotransmission, which is at least partly mediated by STAT3-mediated transcriptional upregulation of ChAT and VAChT.

Original languageEnglish
Pages (from-to)2020-2032
Number of pages13
JournalNeuropsychopharmacology
Volume33
Issue number8
DOIs
Publication statusPublished - 2008 Jul

Fingerprint

Nose
Alzheimer Disease
Choline O-Acetyltransferase
Vesicular Acetylcholine Transport Proteins
Up-Regulation
Central Nervous System
Cerebral Ventricles
Poisons
Olfactory Bulb
Cholinergic Antagonists
Amyloid
Synaptic Transmission
Pharmaceutical Preparations
Cholinergic Agents
Colivelin
Phosphorylation
Neurons
Messenger RNA
humanin
In Vitro Techniques

Keywords

  • Activity-dependent neurotrophic factor
  • Alzheimer's disease
  • Colivelin
  • Humanin
  • Memory impairment

ASJC Scopus subject areas

  • Pharmacology

Cite this

Nasal Colivelin treatment ameliorates memory impairment related to Alzheimer's disease. / Yamada, Marina; Chiba, Tomohiro; Sasabe, Jumpei; Terashita, Kenzo; Aiso, Sadakazu; Matsuoka, Masaaki.

In: Neuropsychopharmacology, Vol. 33, No. 8, 07.2008, p. 2020-2032.

Research output: Contribution to journalArticle

Yamada, Marina ; Chiba, Tomohiro ; Sasabe, Jumpei ; Terashita, Kenzo ; Aiso, Sadakazu ; Matsuoka, Masaaki. / Nasal Colivelin treatment ameliorates memory impairment related to Alzheimer's disease. In: Neuropsychopharmacology. 2008 ; Vol. 33, No. 8. pp. 2020-2032.
@article{6f8ed7cd82464ac1a02dd9ebb8742279,
title = "Nasal Colivelin treatment ameliorates memory impairment related to Alzheimer's disease",
abstract = "Humanin (HN) and its derivatives, such as Colivelin (CLN), suppress neuronal death induced by insults related to Alzheimer's disease (AD) by activating STAT3 in vitro. They also ameliorate functional memory impairment of mice induced by anticholinergic drugs or soluble toxic amyloid-β (Aβ) in vivo when either is directly administered into the cerebral ventricle or intraperitoneally injected. However, the mechanism underlying the in vivo effect remains uncharacterized. In addition, from the standpoint of clinical application, drug delivery methods that are less invasive and specific to the central nervous system (CNS) should be developed. In this study, we show that intranasally (i.n.) administered CLN can be successfully transferred to CNS via the olfactory bulb. Using several behavioral tests, we have demonstrated that i.n. administered CLN ameliorates memory impairment of AD models in a dose-responsive manner. Attenuation of AD-related memory impairment by HN derivatives such as CLN appears to be correlated with an increase in STAT3 phosphorylation levels in the septohippocampal region, suggesting that anti-AD activities of HN derivatives may be mediated by activation of STAT3 in vivo as they are in vitro. We further demonstrate that CLN treatment inhibits an Aβ induced decrease in the number of choline acetyltransferase (ChAT)-positive neurons in the medial septum. Combined with the finding that HN derivatives upregulate mRNA expression of neuronal ChAT and vesicular acetylcholine transporter (VAChT) in vitro, it is assumed that CLN may ameliorate memory impairment of AD models by supporting cholinergic neurotransmission, which is at least partly mediated by STAT3-mediated transcriptional upregulation of ChAT and VAChT.",
keywords = "Activity-dependent neurotrophic factor, Alzheimer's disease, Colivelin, Humanin, Memory impairment",
author = "Marina Yamada and Tomohiro Chiba and Jumpei Sasabe and Kenzo Terashita and Sadakazu Aiso and Masaaki Matsuoka",
year = "2008",
month = "7",
doi = "10.1038/sj.npp.1301591",
language = "English",
volume = "33",
pages = "2020--2032",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Nasal Colivelin treatment ameliorates memory impairment related to Alzheimer's disease

AU - Yamada, Marina

AU - Chiba, Tomohiro

AU - Sasabe, Jumpei

AU - Terashita, Kenzo

AU - Aiso, Sadakazu

AU - Matsuoka, Masaaki

PY - 2008/7

Y1 - 2008/7

N2 - Humanin (HN) and its derivatives, such as Colivelin (CLN), suppress neuronal death induced by insults related to Alzheimer's disease (AD) by activating STAT3 in vitro. They also ameliorate functional memory impairment of mice induced by anticholinergic drugs or soluble toxic amyloid-β (Aβ) in vivo when either is directly administered into the cerebral ventricle or intraperitoneally injected. However, the mechanism underlying the in vivo effect remains uncharacterized. In addition, from the standpoint of clinical application, drug delivery methods that are less invasive and specific to the central nervous system (CNS) should be developed. In this study, we show that intranasally (i.n.) administered CLN can be successfully transferred to CNS via the olfactory bulb. Using several behavioral tests, we have demonstrated that i.n. administered CLN ameliorates memory impairment of AD models in a dose-responsive manner. Attenuation of AD-related memory impairment by HN derivatives such as CLN appears to be correlated with an increase in STAT3 phosphorylation levels in the septohippocampal region, suggesting that anti-AD activities of HN derivatives may be mediated by activation of STAT3 in vivo as they are in vitro. We further demonstrate that CLN treatment inhibits an Aβ induced decrease in the number of choline acetyltransferase (ChAT)-positive neurons in the medial septum. Combined with the finding that HN derivatives upregulate mRNA expression of neuronal ChAT and vesicular acetylcholine transporter (VAChT) in vitro, it is assumed that CLN may ameliorate memory impairment of AD models by supporting cholinergic neurotransmission, which is at least partly mediated by STAT3-mediated transcriptional upregulation of ChAT and VAChT.

AB - Humanin (HN) and its derivatives, such as Colivelin (CLN), suppress neuronal death induced by insults related to Alzheimer's disease (AD) by activating STAT3 in vitro. They also ameliorate functional memory impairment of mice induced by anticholinergic drugs or soluble toxic amyloid-β (Aβ) in vivo when either is directly administered into the cerebral ventricle or intraperitoneally injected. However, the mechanism underlying the in vivo effect remains uncharacterized. In addition, from the standpoint of clinical application, drug delivery methods that are less invasive and specific to the central nervous system (CNS) should be developed. In this study, we show that intranasally (i.n.) administered CLN can be successfully transferred to CNS via the olfactory bulb. Using several behavioral tests, we have demonstrated that i.n. administered CLN ameliorates memory impairment of AD models in a dose-responsive manner. Attenuation of AD-related memory impairment by HN derivatives such as CLN appears to be correlated with an increase in STAT3 phosphorylation levels in the septohippocampal region, suggesting that anti-AD activities of HN derivatives may be mediated by activation of STAT3 in vivo as they are in vitro. We further demonstrate that CLN treatment inhibits an Aβ induced decrease in the number of choline acetyltransferase (ChAT)-positive neurons in the medial septum. Combined with the finding that HN derivatives upregulate mRNA expression of neuronal ChAT and vesicular acetylcholine transporter (VAChT) in vitro, it is assumed that CLN may ameliorate memory impairment of AD models by supporting cholinergic neurotransmission, which is at least partly mediated by STAT3-mediated transcriptional upregulation of ChAT and VAChT.

KW - Activity-dependent neurotrophic factor

KW - Alzheimer's disease

KW - Colivelin

KW - Humanin

KW - Memory impairment

UR - http://www.scopus.com/inward/record.url?scp=45149115313&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45149115313&partnerID=8YFLogxK

U2 - 10.1038/sj.npp.1301591

DO - 10.1038/sj.npp.1301591

M3 - Article

VL - 33

SP - 2020

EP - 2032

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 8

ER -